Cargando…

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay

BACKGROUND: In 2020, pembrolizumab was approved as a therapy for triple-negative breast cancer (TNBC) with the companion diagnostic DAKO 22C3 programmed death ligand-1 (PD-L1) immunohistochemistry assay. The study aimed to determine the landscape of PD-L1 expression as detected by the DAKO 22C3 PD-L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Danziger, Natalie, Sokol, Ethan S, Graf, Ryon P, Hiemenz, Matthew C, Maule, Jake, Parimi, Vamsi, Palmieri, Carlo, Pusztai, Lajos, Ross, Jeffrey S, Huang, Richard S P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Cancer Diagnostics and Molecular Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078903/ https://www.ncbi.nlm.nih.gov/pubmed/36866462 http://dx.doi.org/10.1093/oncolo/oyad025

Ejemplares similares

Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation
por: Huang, Richard S P, et al.
Publicado: (2022)

Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases
por: Huang, Richard S P, et al.
Publicado: (2022)

Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study
por: Necchi, Andrea, et al.
Publicado: (2022)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms
por: Liu, Man, et al.
Publicado: (2023)

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
por: Ross, Jeffrey S., et al.
Publicado: (2020)

Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901)
por: Peng, Wenying, et al.
Publicado: (2022)

Homologous Recombination Deficiency: Concepts, Definitions, and Assays
por: Stewart, Mark D, et al.
Publicado: (2022)

Genomic landscape of 891 RET fusions detected across diverse solid tumor types
por: Parimi, Vamsi, et al.
Publicado: (2023)

EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE(®)
por: Sapalidis, Konstantinos, et al.
Publicado: (2019)

Diagnostic Accuracy of Cell Block and Immunohistochemistry in Effusion Cytology
por: Batool, Saima, et al.
Publicado: (2023)

The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs
por: Mohamed, Luqmaan, et al.
Publicado: (2022)

Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network
por: Dias-Santagata, Dora, et al.
Publicado: (2022)

Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer
por: Murugesan, Karthikeyan, et al.
Publicado: (2022)

Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms
por: Franses, Joseph W., et al.
Publicado: (2017)

Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing
por: Patel, Nirali M., et al.
Publicado: (2017)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Post-chemotherapy Changes in Bone Marrow in Acute Leukemia With Emphasis on Detection of Residual Disease by Immunohistochemistry
por: Ayyanar, Pavithra, et al.
Publicado: (2021)

Association Between the Immunohistochemistry Expression of E-cadherin, Beta-Catenin, and CD44 in Colorectal Adenocarcinoma
por: Tunuguntla, Amrutha, et al.
Publicado: (2023)

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers
por: Hirshfield, Kim M., et al.
Publicado: (2016)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer
por: Guo, Yun, et al.
Publicado: (2020)

Combined Expression of Plasma Thrombospondin‐2 and CA19‐9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach
por: Le Large, Tessa Y.S., et al.
Publicado: (2020)

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions
por: Jardim, Denis L., et al.
Publicado: (2020)

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors
por: Takeda, Masayuki, et al.
Publicado: (2021)

One‐Step Polymerase Chain Reaction‐Free Nanowire‐Based Plasma Cell‐Free DNA Assay to Detect EML4‐ALK Fusion and to Monitor Resistance in Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2021)

Validation of a Circulating Tumor DNA‐Based Next‐Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing
por: Al Zoughbi, Wael, et al.
Publicado: (2021)

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations
por: Koopman, Bart, et al.
Publicado: (2020)

Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary
por: Fusco, Michael J, et al.
Publicado: (2022)

Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents
por: Janse van Rensburg, Helena J, et al.
Publicado: (2022)

The Essentials of Multiomics
por: Marshall, John L, et al.
Publicado: (2022)

A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
por: Pauli, Chantal, et al.
Publicado: (2021)

Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma
por: Yu, Pengfei, et al.
Publicado: (2021)

Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice
por: Choucair, Khalil, et al.
Publicado: (2022)

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings
por: Sturgill, Emma G, et al.
Publicado: (2022)

Artificial Intelligence-based Radiomics in the Era of Immuno-oncology
por: Kang, Cyra Y, et al.
Publicado: (2022)

Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic
por: Napolitano, Stefania, et al.
Publicado: (2022)

Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers
por: Girard, Nicolas, et al.
Publicado: (2022)

Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board
por: Green, Michelle F, et al.
Publicado: (2023)

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
por: Liu, Fangcen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uj99jic7r12pd520lifccmc7rt